Guangzhou Sinogen Pharmaceutical was selected in the 5th Top 50 Biotechnology Innovation Enterprises List.

On December 29, 2022, the 5th Guangdong-Hong Kong-Macao Greater Bay Area Top 50 Biotechnology Innovation Enterprises Award Ceremony was held in Nansha, Guangzhou. Sinogen Pharmaceutical was rated as one of the top 50 biotechnology innovation enterprises in the Greater Bay Area in 2022 - leading enterprises and industry influential enterprises, and Dr. Allan Zijian Zhao was honored as the expert of the year.

The fifth award of the top 50 biotech innovation enterprises was awarded to recognize the outstanding biotech enterprises and industry leaders who are still determined to innovate and dare to explore at the present time. The top 50 list was jointly reviewed by authoritative industry experts, professional investment institutions, and hospital/association representatives. It took more than five months to comprehensively build the top 50 list of biotechnology innovation enterprises from multiple perspectives such as enterprise size, development status, innovation, progressiveness, market prospects, and financing progress.

Round-table Forum: How to speed up the development of the Greater Bay Area into a world-class biomedical industry innovation highland
During the conference, the Biotechnology Innovation and Development Summit was also held. Xie Jiasheng, Executive President of Guangdong Medical Valley, presided over the round-table dialogue on how to accelerate the development of the Guangdong-Hong Kong-Macao Greater Bay Area to a world-class biomedical industry innovation highland, and discussed the future development of biotechnology in the Greater Bay Area with biotech investors, scholars, hospital representatives, and enterprise representatives. It carried out multi-dimensional exchanges and discussions, in-depth analyzed the difficulties and challenges encountered by the biotechnology industry in the Greater Bay Area, and expressed their views on the future development direction of cross-border cooperation and innovation in biotechnology.

Dr. Allan Zijian Zhao, CEO of Sinogen Pharmaceutical, said that innovation is the only way for Chinese pharmaceutical enterprises in the future. 

Broad-spectrum anti-tumor drugs have a wide range of application scenarios, and are applicable to the early adjuvant treatment and various lines of treatment for many cancers, throughout the whole process of cancer treatment.

<END>